Inhibition of telomerase activity and cell proliferation by a reverse transcriptase inhibitor in gynaecological cancer cell lines

被引:62
作者
Murakami, J [1 ]
Nagai, N [1 ]
Shigemasa, K [1 ]
Ohama, K [1 ]
机构
[1] Hiroshima Univ, Sch Med, Dept Obstet & Gynecol, Minami Ku, Hiroshima 734, Japan
关键词
telomerase; telomere; RTI; enhancement of cisplatin; inhibition of cell growth;
D O I
10.1016/S0959-8049(99)00037-4
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Telomerase is a ribonucleoprotein which has a RNA template to bind and extend telomere ends, so prolonging the life of tumour cells. The aim of this study was to determine whether transcriptase function of telomerase could be inhibited by the reverse transcriptase inhibitors (RTI); azydothymidine (AZT), dideoxyinosine (ddI) and AZT-5' triphosphate(AZT-TP). We examined their effects on the proliferation of cancer cells and the antitumour effects of cisplatin in vitro. The three agents did not cause major changes in telomerase activity or telomere length in MCAS cells. However, in HEC-1 cells changes in telomerase activity and telomere length were observed that were dependent on the RTI concentration and duration of exposure. ddI and AZT-TP reduced telomerase activity and shortened the length of the telomere. In the presence of RTI, the antitumour effects of cisplatin were enhanced. This was particularly evident in HEC-1 cells where there was a marked reduction in cell proliferation, appearance of morphological changes and senescent-like cells in the presence of ddI or AZT-TP. In MCAS cells, TP53 expression was increased by ddI and AZT-TP, while p21 expression was unchanged. In HEC-1 cells the expression of both TP53 and P21 was increased by ddI. Continuous administration of RTI enhanced the cell growth inhibition of cisplatin. RTI also inhibited the proliferation of some cells. (C) 1999 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:1027 / 1034
页数:8
相关论文
共 33 条
[1]  
BACCHETTI S, 1995, INT J ONCOL, V7, P423
[2]  
BEDFORD P, 1988, CANCER RES, V48, P3019
[3]   Telomerase activity: A biomarker of cell proliferation, not malignant transformation [J].
Belair, CD ;
Yeager, TR ;
Lopez, PM ;
Reznikoff, CA .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (25) :13677-13682
[4]  
Bottalico C, 1996, ANTICANCER RES, V16, P3865
[5]   Telomerase and early detection of cancer: A National Cancer Institute workshop [J].
Breslow, RA ;
Shay, JW ;
Gazdar, AF ;
Srivastava, S .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1997, 89 (09) :618-623
[6]   Inhibition of telomerase activity by cisplatin in human testicular cancer cells [J].
Burger, AM ;
Double, JA ;
Newell, DR .
EUROPEAN JOURNAL OF CANCER, 1997, 33 (04) :638-644
[7]  
Chollet P, 1996, ANN ONCOL, V7, P1065
[8]   THE RNA COMPONENT OF HUMAN TELOMERASE [J].
FENG, JL ;
FUNK, WD ;
WANG, SS ;
WEINRICH, SL ;
AVILION, AA ;
CHIU, CP ;
ADAMS, RR ;
CHANG, E ;
ALLSOPP, RC ;
YU, JH ;
LE, SY ;
WEST, MD ;
HARLEY, CB ;
ANDREWS, WH ;
GREIDER, CW ;
VILLEPONTEAU, B .
SCIENCE, 1995, 269 (5228) :1236-1241
[9]   Irreversible telomere shortening by 3′-azido-2′,3′-dideoxythymidine (AZT) treatment [J].
Gomez, DE ;
Tejera, AM ;
Olivero, OA .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1998, 246 (01) :107-110
[10]   Identification of determinants for inhibitor binding within the RNA active site of human telomerase using PNA scanning [J].
Hamilton, SE ;
Pitts, AE ;
Katipally, RR ;
Jia, XY ;
Rutter, JP ;
Davies, BA ;
Shay, JW ;
Wright, WE ;
Corey, DR .
BIOCHEMISTRY, 1997, 36 (39) :11873-11880